Synaptic Impairment in Alzheimer's Disease: A Dysregulated Symphony

Trends Neurosci. 2017 Jun;40(6):347-357. doi: 10.1016/j.tins.2017.04.002. Epub 2017 May 8.

Abstract

Alzheimer's disease (AD) is characterized by memory loss, cognitive decline, and devastating neurodegeneration, not only as a result of the extracellular accumulation of beta-amyloid peptide (Aβ) and intracellular accumulation of tau, but also as a consequence of the dysfunction and loss of synapses. Although significant advances have been made in our understanding of the relationship of the pathological role of Aβ and tau in synapse dysfunction, several questions remain as to how Aβ and tau interdependently cause impairments in synaptic function in AD. Overall, more insight into these questions should enable researchers in this field to develop novel therapeutic targets to mitigate or delay the cognitive deficits associated with this devastating disease.

Keywords: Alzheimer’s disease; beta-amyloid; synaptic impairment; tau.

Publication types

  • Review
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alzheimer Disease / metabolism*
  • Amyloid beta-Peptides / metabolism*
  • Animals
  • Humans
  • Synapses / metabolism*
  • tau Proteins / metabolism*

Substances

  • Amyloid beta-Peptides
  • tau Proteins